943153-51-3 Usage
Uses
Used in Pharmaceutical Industry:
3-Pyridinecarbonitrile, 5-bromo-6-methoxyis used as a building block for the synthesis of various biologically active compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agricultural Industry:
3-Pyridinecarbonitrile, 5-bromo-6-methoxyis used as a building block for the synthesis of agrochemicals. Its potential antifungal and anti-inflammatory properties make it a valuable component in the development of new pesticides and other agricultural products.
Used in Medicinal Chemistry Research:
3-Pyridinecarbonitrile, 5-bromo-6-methoxyis used as a target for further research and development in the field of medicinal chemistry. Its unique structure and potential properties make it an interesting candidate for the discovery of new drugs and treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 943153-51-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,3,1,5 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 943153-51:
(8*9)+(7*4)+(6*3)+(5*1)+(4*5)+(3*3)+(2*5)+(1*1)=163
163 % 10 = 3
So 943153-51-3 is a valid CAS Registry Number.
943153-51-3Relevant articles and documents
(AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
-
Paragraph 0368, (2020/10/21)
The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
ROR-GAMMA INHIBITORS
-
Page/Page column 257, (2019/04/26)
The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.
Compounds with medicinal effects due to interaction with the glucocorticoid receptor
-
Page/Page column 17-18, (2010/11/27)
The invention provides for compounds having the structure according to the formula I
